Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Merck KGaA (Xetra:MRK) said first-line treatment with Erbitux cetuximab plus FOLFIRI chemotherapy missed the primary endpoint of significantly
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury